1227633-49-9
1227633-49-9 structure
- Name: StemRegenin 1 (SR1)
- Chemical Name: 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol
- CAS Number: 1227633-49-9
- Molecular Formula: C24H23N5OS
- Molecular Weight: 429.537
- Catalog: Biochemical Inhibitor Metabolism AhR antagonist
- Create Date: 2017-06-03 04:14:06
- Modify Date: 2025-08-25 12:01:48
-
StemRegenin 1 is a potent aryl hydrocarbon receptor (AhR) antagonist with IC50 of 127 nM.
| Name | 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol |
|---|---|
| Synonyms |
4-(2-{[2-(1-Benzothiophen-3-yl)-9-isopropyl-9H-purin-6-yl]amino}ethyl)phenol
Phenol, 4-[2-[[2-benzo[b]thien-3-yl-9-(1-methylethyl)-9H-purin-6-yl]amino]ethyl]- StemRegenin1 StemRegenin 1 SR1 |
| Description | StemRegenin 1 is a potent aryl hydrocarbon receptor (AhR) antagonist with IC50 of 127 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 127 nM (AhR)[1] |
| In Vitro | StemRegenin 1 (SR1) acts by antagonizing the aryl hydrocarbon receptor (AhR). StemRegenin 1 increases the number of CD34+ cells after 5 to 7 days with an EC50 of ~120 nM. StemRegenin 1 inhibits photoaffinity ligand (PAL) binding (IC50=40 nM) These results support the conclusion that StemRegenin 1 -induced CD34+ cell expansion is mediated through direct binding and inhibition of the AhR[1]. An aryl hydrocarbon receptor antagonist, StemRegenin 1 (SR1), robustly promotes ex vivo expansion of human CD34+ cells. StemRegenin 1 treatment accelerates the proliferation of CD34+ cells and decreases the expression levels of VentX[2]. |
| Cell Assay | A quantity of 250,000 CB-derived CD34+ cells are cultured with control conditions (DMSO, 0.01%) or StemRegenin 1 (0.75 μM) for 3 weeks. At this point control cultures had expanded 1080-fold and StemRegenin 1 treated cells expanded 2024-fold relative to starting cell numbers. A quantity of 30 to 30,000 uncultured CD34+ CB-derived cells or a fraction of the final culture equivalent to 30 to 10,000 starting cells are transplanted. The cells are injected intravenously via the retro-orbital route into sub-lethally irradiated (300 rads, 200 rads) 6- to 10-week-old NSG mice. Engraftment is performed within 24 h after irradiation. Engraftment is monitored by flow cytometric analysis of blood obtained via retro-orbital sinus or bone marrow using anti-human CD45 and anti-mouse CD45 antibodies. The mice are sacrificed between 13-16 weeks posttransplantation; bone marrow (from both femurs and tibiae), spleen and thymus are collected for analysis. For secondary engraftment, 50% of the bone marrow from each recipient mouse is transplanted into one secondary sub-lethally irradiated NSG mouse. Fifteen weeks after transplantation, bone marrow is harvested from the secondary mice and analyzed by flow cytometry[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 622.9±65.0 °C at 760 mmHg |
| Molecular Formula | C24H23N5OS |
| Molecular Weight | 429.537 |
| Flash Point | 330.5±34.3 °C |
| Exact Mass | 429.162323 |
| PSA | 104.10000 |
| LogP | 5.10 |
| Appearance | white solid |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.721 |
| Storage condition | +2C to +8C |